Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
CA 2093643 C · Owner: Genetics Institute, Inc. · Inventors: Mccoy, John; Lavallie, Edward R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the, DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxinlike molecule, or within the thioredoxin-like molecule for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell produces high , levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm may be selectively …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 6, 1992 and granted October 30, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 6, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 6, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.